Literature DB >> 8101762

Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.

M Ogasawara1, S A Rosenberg.   

Abstract

Gene therapy for cancer is being tested in clinical trials using tumor-infiltrating lymphocytes (TIL) or tumor cells modified by the insertion of genes coding for interleukin 2 or tumor necrosis factor alpha. In the present study, we investigated the feasibility of transducing human tumor cells with genes coding for gamma-interferon (IFN gamma) or alpha-interferon (IFN alpha), which are two other cytokines that can enhance host antitumor immune responses. Tumor cells from 12 melanoma and 2 renal cell carcinoma patients were transduced with retroviral vectors containing the gene for IFN gamma. Northern blot analysis showed IFN gamma transcripts only in the IFN gamma gene-transduced cells. In both IFN gamma-secreting and non-secreting tumor lines, the cell surface expression of HLA class I and class II molecules increased following transduction. However, the magnitude of the increase in HLA expression appeared to be greater in tumor lines secreting IFN gamma. Two melanoma cell lines were successfully transduced with an IFN alpha retroviral vector. Melanoma cells transduced with the IFN alpha gene contained IFN alpha RNA transcripts and secreted large amounts of IFN alpha. In contrast to cells transduced with the IFN gamma gene, the expression of HLA class II molecules was not increased in the IFN alpha gene-transduced cells. Finally, we tested the ability of HLA.DR+ melanoma cells, which had been transduced with the IFN gamma gene, to stimulate specific cytokine release by autologous CD4+ TIL. Specific secretion of cytokine by TIL occurred when the TIL and IFN gamma gene-transduced tumor cells were cultured together but not when TIL were cultured alone or with control nontransduced tumor cells. These results suggest that molecules newly expressed on the transduced cells promoted antigen presentation and T-cell responses against the transduced tumor cells. The insertion of the IFN gamma gene into melanoma cells may be useful either for active immunization against melanoma or for the generation of TIL to be used in adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101762

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Immunotherapy of a murine T cell lymphoma localized to the brain.

Authors:  V K Ghant; N S Hiramoto; G Y Gillespie; D K Gauthier; R N Hiramoto
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  Transduction of human hepatocellular carcinoma cells with human alpha-interferon gene via retroviral vector.

Authors:  Shu-Bing Qian; Shi-Shu Chen
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

Review 3.  Gene therapy. Clinical potential and relationship to drug treatment.

Authors:  K A Whartenby; A J Marrogi; S M Freeman
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

Review 4.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 5.  Skin growths in the aged. Treatment considerations.

Authors:  W Frank; G S Rogers
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

6.  Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

Authors:  Yu Yu; Hyun-Ii Cho; Dapeng Wang; Kane Kaosaard; Claudio Anasetti; Esteban Celis; Xue-Zhong Yu
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

Review 7.  Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.

Authors:  Meysam Mosallaei; Miganoosh Simonian; Naeim Ehtesham; Mohammad Reza Karimzadeh; Nasim Vatandoost; Babak Negahdari; Rasoul Salehi
Journal:  Cancer Gene Ther       Date:  2020-05-18       Impact factor: 5.987

8.  Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice.

Authors:  Hae-Ran Park; Eun-Jin Ju; Sung-Kee Jo; Uhee Jung; Sung-Ho Kim; Sung-Tae Yee
Journal:  BMC Cancer       Date:  2009-03-17       Impact factor: 4.430

9.  The Chinese Herbal Mixture Tien-Hsien Liquid Augments the Anticancer Immunity in Tumor Cell-Vaccinated Mice.

Authors:  Pei-Ming Yang; Jia-Ling Du; George Nian-Kae Wang; Jean-San Chia; Wei-Bin Hsu; Pin-Ching Pu; Andy Sun; Chun-Pin Chiang; Won-Bo Wang
Journal:  Integr Cancer Ther       Date:  2016-06-01       Impact factor: 3.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.